Shingles mRNA vaccine safety and immune response study
Part of Infections clinical trials.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older (phase 1) or 50 years or older (phase 2).
- You never had shingles or chickenpox as an adult, and never got a shingles or chickenpox vaccine before.
- You don't have poorly controlled health conditions like high blood pressure or diabetes.
- You don't have a weak immune system or take medicines that suppress it (like high-dose steroids for more than 14 days).
- You are not pregnant or breastfeeding, and agree to use effective birth control for 6 months after the last dose.
- You have no history of heart muscle inflammation (myocarditis), autoimmune diseases, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests an experimental shingles vaccine in adults aged 40 and older. It aims to see if the vaccine is safe and helps your body build immunity against shingles.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
This study tests a new shingles vaccine to make sure each batch works the same way. If you are 40 or older and have never had shingles or the shingles vaccine, you may qualify.
This trial tests a new shingles vaccine to see if it's safe and helps the body build immunity. It is for healthy adults aged 50 and older who have not had shingles before.
This trial tests a new mRNA vaccine (IN001) to prevent shingles. It is for healthy adults aged 50 to 79 who have never had shingles or been vaccinated against it.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.